Russia can maintain its military forces in Syria on its own — LavrovRussian Politics & Diplomacy January 17, 11:57
Lavrov says future of Russia-US ties will be clear after new administration takes officeRussian Politics & Diplomacy January 17, 11:32
Russian top diplomat believes Trump will have no double standards on war on terrorRussian Politics & Diplomacy January 17, 11:17
Lavrov says US stepped up ‘recruitment activity’ against Russian diplomatsRussian Politics & Diplomacy January 17, 11:06
Russian Foreign Minister Lavrov holds annual press conferenceRussian Politics & Diplomacy January 17, 10:37
Foreign ministry spokeswoman slams CNN after publication of all Trump's 'Russia remarks'Russian Politics & Diplomacy January 17, 9:46
Global elite gathering at Davos to discuss world economy challengesBusiness & Economy January 17, 9:29
Diplomat: Moscow knows very little about Trump's plans for Iran nuclear dealRussian Politics & Diplomacy January 17, 9:18
Diplomat states 'practically no grounds' for accusing Damascus of chemical attacksRussian Politics & Diplomacy January 17, 8:29
NOVOSIBIRSK, June 9. /TASS/. A new vaccine to protect against Ebola virus disease developed by Russia’s Vector research center of virology and biotechnology has successfully undergone the first stage of clinical tests, the acting director general of the research center told reporters on the sidelines of the international forum for technological development on Thursday.
"The first phase of clinical tests has been completed. It is now on approval at the Russian Ministry of Healthcare. We are waiting for a second phase," Valery Mikheyev said.
According to the World Health Organization (WHO), more than 11,300 people have died from Ebola in West Africa, primarily in Guinea, Sierra Leone and Liberia. More than 28,600 were infected. In January, Russia informed the WHO executive committee about its anti-Ebola vaccines.
The World Health Organization describes Ebola virus disease (formerly known as Ebola haemorrhagic fever) as "a severe, often fatal illness, with a case fatality rate of up to 90%." Until now, there has been no known cure or vaccine for the disease. The only treatment offered is "supportive intensive care." During an outbreak, those at higher risk of infection are health workers, family members and others in close contact with sick people and deceased patients.